The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line-Reference-Cited by-同舟云学术

The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line

Published:2017-10 Issue: Volume:190 Page:20-25
ISSN:0165-2478
Container-title:Immunology Letters
language:en
Short-container-title:Immunology Letters

Author:

Akiyama Yasuto,Nonomura Chizu,Ashizawa Tadashi,Iizuka Akira,Kondou Ryota,Miyata Haruo,Sugino Takashi,Mitsuya Koichi,Hayashi Nakamasa,Nakasu Yoko,Asai Akira,Ito Mamoru,Kiyohara Yoshio,Yamaguchi Ken

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference29 articles.

1. Stat3　and　Stat4:　members of the family of signal transducers and activators of transcription;Zhong;Proc. Natl. Acad. Sci. U. S. A.,1994

2. The role of STATs in transcriptional control and their impact on cellular functions;Bromberg;Oncogene,2000

3. Crosstalk between cancer and immune cells: role of STAT3 in the tumor microenvironment;Yu;Nat. Rev. Immunol.,2007

4. Regulation of the innate and adaptive immune responses by stat-3 signaling in tumor cells;Wang;Nat. Med.,2004

5. Role of Stat3 in suppressing anti-tumor immunity;Kortylewski;Curr. Opin. Immunol.,2008

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selective STAT3 inhibitor STX-0119 alleviates osteoarthritis progression by modulating the STAT3/PPARγ signaling pathway;Biochemical Pharmacology;2024-09

2. Insights of immune cell heterogeneity, tumor-initiated subtype transformation, drug resistance, treatment and detecting technologies in glioma microenvironment;Journal of Advanced Research;2024-08

3. Humanized mouse models for immuno-oncology research;Nature Reviews Clinical Oncology;2023-01-12

4. Zinc transporter LIV1: A promising cell surface target for triple negative breast cancer;Journal of Cellular Physiology;2022-10

5. Small-Molecule PROTACs for Cancer Immunotherapy;Molecules;2022-08-25